{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:59:35Z","timestamp":1760551175658,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,18]],"date-time":"2020-07-18T00:00:00Z","timestamp":1595030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,18]],"date-time":"2020-07-18T00:00:00Z","timestamp":1595030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s12012-020-09589-z","type":"journal-article","created":{"date-parts":[[2020,7,18]],"date-time":"2020-07-18T11:02:48Z","timestamp":1595070168000},"page":"12-16","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Chemotherapy with a Pegylated Liposomal Doxorubicin-Containing Regimen in Newly Diagnosed Hodgkin Lymphoma Patients"],"prefix":"10.1007","volume":"21","author":[{"given":"Weiping","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingzi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingyan","family":"Ping","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaopei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5451-6481","authenticated-orcid":false,"given":"Yuqin","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,18]]},"reference":[{"key":"9589_CR1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow, S. H., Campo, E., Pileri, S. A., et al. (2016). The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood, 127, 2375\u20132390.","journal-title":"Blood"},{"issue":"12","key":"9589_CR2","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1001\/jamaoncol.2019.2996","volume":"5","author":"D Abate","year":"2019","unstructured":"Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Abate, D., et al. (2019). Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: A systematic analysis for the Global Burden of Disease Study. JAMA Oncology, 5(12), 1749\u20131768.","journal-title":"JAMA Oncology"},{"key":"9589_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13045-019-0785-7","volume":"12","author":"W Liu","year":"2019","unstructured":"Liu, W., Liu, J., Song, Y., et al. (2019). Burden of lymphoma in China, 2006\u20132016: An analysis of the Global Burden of Disease Study 2016. Journal of Hematology & Oncology, 12, 115.","journal-title":"Journal of Hematology & Oncology"},{"key":"9589_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-019-0706-9","volume":"12","author":"W Liu","year":"2019","unstructured":"Liu, W., Liu, J., Song, Y., et al. (2019). Mortality of lymphoma and myeloma in China, 2004\u20132017: An observational study. Journal of Hematology & Oncology, 12, 22.","journal-title":"Journal of Hematology & Oncology"},{"key":"9589_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3037","author":"W Liu","year":"2020","unstructured":"Liu, W., Ji, X., Song, Y., et al. (2020). Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades. Cancer Medicine. https:\/\/doi.org\/10.1002\/cam4.3037.","journal-title":"Cancer Medicine"},{"key":"9589_CR6","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/cam4.655","volume":"5","author":"M Koshy","year":"2016","unstructured":"Koshy, M., Fairchild, A., Son, C. H., et al. (2016). Improved survival time trends in Hodgkin's lymphoma. Cancer Medicine, 5, 997\u20131003.","journal-title":"Cancer Medicine"},{"key":"9589_CR7","first-page":"3035","volume":"37","author":"S Master","year":"2017","unstructured":"Master, S., Koshy, N., Wilkinson, B., et al. (2017). Effect of radiation therapy on survival in Hodgkin's lymphoma: A SEER data analysis. Anticancer Research, 37, 3035\u20133043.","journal-title":"Anticancer Research"},{"key":"9589_CR8","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1093\/annonc\/mdx413","volume":"29","author":"C Buske","year":"2018","unstructured":"Buske, C., Hutchings, M., Ladetto, M., et al. (2018). ESMO Consensus Conference on malignant lymphoma: General perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma. Annals of Oncology, 29, 544\u2013562.","journal-title":"Annals of Oncology"},{"key":"9589_CR9","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson, B. D., Pfistner, B., Juweid, M. E., et al. (2007). Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579\u2013586.","journal-title":"Journal of Clinical Oncology"},{"key":"9589_CR10","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1200\/JCO.2017.75.2543","volume":"36","author":"A Gallamini","year":"2018","unstructured":"Gallamini, A., Tarella, C., Viviani, S., et al. (2018). Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography\/computed tomography scan after two ABVD cycles: Long-term results of the GITIL\/FIL HD 0607 Trial. Journal of Clinical Oncology, 36, 454\u2013462.","journal-title":"Journal of Clinical Oncology"},{"key":"9589_CR11","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","volume":"390","author":"P Borchmann","year":"2018","unstructured":"Borchmann, P., Goergen, H., Kobe, C., et al. (2018). PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): Final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet, 390, 2790\u20132802.","journal-title":"Lancet"},{"key":"9589_CR12","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1200\/JCO.2012.47.9774","volume":"31","author":"D Wongso","year":"2013","unstructured":"Wongso, D., Fuchs, M., Pl\u00fctschow, A., et al. (2013). Treatment-related mortality in patients with advanced-stage hodgkin lymphoma: An analysis of the german hodgkin study group. Journal of Clinical Oncology, 31, 2819\u20132824.","journal-title":"Journal of Clinical Oncology"},{"key":"9589_CR13","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/bjc.2017.476","volume":"118","author":"S de Vries","year":"2018","unstructured":"de Vries, S., Schaapveld, M., van Nimwegen, F. A., et al. (2018). High burden of subsequent malignant neoplasms and cardiovascular disease in long-term Hodgkin lymphoma survivors. British Journal of Cancer, 118, 887\u2013895.","journal-title":"British Journal of Cancer"},{"key":"9589_CR14","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","volume":"175","author":"FA van Nimwegen","year":"2015","unstructured":"van Nimwegen, F. A., Schaapveld, M., Janus, C. P., et al. (2015). Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Internal Medicine, 175, 1007\u20131017.","journal-title":"JAMA Internal Medicine"},{"key":"9589_CR15","doi-asserted-by":"crossref","unstructured":"Cutter, D. J., Schaapveld, M., Darby, S. C., et al. (2015). Risk of valvular heart disease after treatment for Hodgkin lymphoma. Journal of the National Cancer Institute, 107, djv008.","DOI":"10.1093\/jnci\/djv008"},{"key":"9589_CR16","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.1200\/JCO.2017.72.4211","volume":"35","author":"T Salz","year":"2017","unstructured":"Salz, T., Zabor, E. C., de Nully, B. P., et al. (2017). Preexisting cardiovascular risk and subsequent heart failure among non-Hodgkin lymphoma survivors. Journal of Clinical Oncology, 35, 3837\u20133843.","journal-title":"Journal of Clinical Oncology"},{"key":"9589_CR17","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1093\/annonc\/mdm090","volume":"18","author":"NL Bartlett","year":"2007","unstructured":"Bartlett, N. L., Niedzwiecki, D., Johnson, J. L., et al. (2007). Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Annals of Oncology, 18, 1071\u20131079.","journal-title":"Annals of Oncology"},{"key":"9589_CR18","doi-asserted-by":"publisher","first-page":"e269","DOI":"10.3324\/haematol.2015.124784","volume":"100","author":"AS Michallet","year":"2015","unstructured":"Michallet, A. S., Guillermin, Y., Deau, B., et al. (2015). Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma. Haematologica, 100, e269\u2013e271.","journal-title":"Haematologica"},{"key":"9589_CR19","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1080\/10428194.2019.1608529","volume":"60","author":"F Salvi","year":"2019","unstructured":"Salvi, F., Luminari, S., Tucci, A., et al. (2019). Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (\u2265 70 years) or cardiopathic patients with Hodgkin lymphoma: A phase-II study from Fondazione Italiana Linfomi (FIL). Leukaemia & Lymphoma, 60, 2890\u20132898.","journal-title":"Leukaemia & Lymphoma"},{"key":"9589_CR20","doi-asserted-by":"publisher","first-page":"5390","DOI":"10.1200\/JCO.2009.23.3239","volume":"27","author":"PJ Hoskin","year":"2009","unstructured":"Hoskin, P. J., Lowry, L., Horwich, A., et al. (2009). Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. Journal of Clinical Oncology, 27, 5390\u20135396.","journal-title":"Journal of Clinical Oncology"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-020-09589-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12012-020-09589-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-020-09589-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T23:30:09Z","timestamp":1626564609000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12012-020-09589-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,18]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["9589"],"URL":"https:\/\/doi.org\/10.1007\/s12012-020-09589-z","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"type":"print","value":"1530-7905"},{"type":"electronic","value":"1559-0259"}],"subject":[],"published":{"date-parts":[[2020,7,18]]},"assertion":[{"value":"22 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Institutional Review Board of Peking University Cancer Hospital & Institute approved this retrospective study and waived the need to obtain patient informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}